The discovery of the Janus kinase (JAK)-signal transducer and activator of transcription
(STAT) pathway arose from investigations of how cells respond to interferons (IFNs) …

Dying mammalian cells emit numerous signals that interact with the host to dictate the
immunological correlates of cellular stress and death. In the absence of reactive antigenic …

The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

Tumours employ various tactics to adapt and eventually resist immune attack. These
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …

The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …

DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that
is thought to explain their exceptional responsiveness to immune checkpoint blockade …

Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …

Interaction of the T cell receptor (TCR) with an MHC-antigenic peptide complex results in
changes at the molecular and cellular levels in T cells. The outside environmental cues are …